

Fiscal Year:	FY 2004	Task Last Updated: FY 04/03/2006	
PI Name:	Schaffler, Mitchell B. Ph.D.		
Project Title:	BONE RECOVERY POTENTIAL AFTER BISPHOSPHONATE AND PTH TREATMENT OF DISUSE OSTEOPOROSIS		
Division Name:	Human Research		
Program/Discipline:	NSBRI Teams		
Program/Discipline--Element/Subdiscipline:	NSBRI Teams--Bone Loss Team		
Joint Agency Name:		TechPort:	No
Human Research Program Elements:	(1) HHC: Human Health Countermeasures		
Human Research Program Risks:	(1) Bone Fracture: Risk of Bone Fracture due to Spaceflight-induced Changes to Bone (2) Osteo: Risk Of Early Onset Osteoporosis Due To Spaceflight		
Space Biology Element:	None		
Space Biology Cross-Element Discipline:	None		
Space Biology Special Category:	None		
PI Email:	Mitchell.Schaffler@mssm.edu	Fax:	FY 212-426-7750
PI Organization Type:	UNIVERSITY	Phone:	212-241-1625
Organization Name:	Mount Sinai School of Medicine		
PI Address 1:	One Gustave L. Levy Place		
PI Address 2:	Box 1188		
PI Web Page:			
City:	New York	State:	NY
Zip Code:	10029-6500	Congressional District:	14
Comments:			
Project Type:	GROUND	Solicitation / Funding Source:	2003 Biomedical Research & Countermeasures 03-OBPR-04
Start Date:	06/01/2004	End Date:	05/31/2008
No. of Post Docs:		No. of PhD Degrees:	
No. of PhD Candidates:		No. of Master' Degrees:	
No. of Master's Candidates:		No. of Bachelor's Degrees:	
No. of Bachelor's Candidates:		Monitoring Center:	NSBRI
Contact Monitor:		Contact Phone:	
Contact Email:			
Flight Program:			
Flight Assignment:			
Key Personnel Changes/Previous PI:			
COI Name (Institution):			
Grant/Contract No.:	NCC 9-58-BL00406		
Performance Goal No.:			
Performance Goal Text:			

Task Description:	Bone loss in microgravity and the resulting bone fragility have been identified by NASA as key barriers to successful long-term space flight. Effective countermeasures must therefore prevent bone loss, but also to maintain the mechanical integrity of the tissue during prolonged space flight and allow rapid recovery of normal function. Disuse osteoporosis in humans and higher mammals results from elevated bone resorption. Thus, targeting osteoclasts with antiresorptive agents like bisphosphonate to prevent bone loss is a key strategy. While anti-resorptive drugs have been the cornerstones of osteoporosis therapy, anabolic agents, such as PTH, that stimulate bone formation represent an important new advance in the treatment of osteoporosis. We hypothesize that PTH may be especially valuable in reversing disuse if the deterioration of bone architecture can be slowed such that the anabolic agent has a better initial bone scaffold on which to work. The studies examine whether bone that remains after bisphosphonate-treatment during long-term immobilization can recover its architecture and mechanical function after restoration of mechanical usage (remobilization). We will then assess whether addition of anabolic PTH during immobilization will improve recovery of disuse bone. Recovery after long-term disuse with bisphosphonate treatment will be examined in an immobilization model. MicroCT imaging will be used to evaluate microstructure, biomechanical testing to assess function and histomorphometry to measure tissue physiological responses.
Rationale for HRP Directed Research:	
Research Impact/Earth Benefits:	
Task Progress:	New project for FY2004; no progress report this period.
Bibliography Type:	Description: (Last Updated: 08/21/2020)